BioSpace News Archive

According to Nova One Advisor, the global diagnostic testing market is valued at USD 211.27 billion in 2023

Medincell (Paris:MEDCL) today announced a collaboration with AbbVie to co-develop and commercialize up to six therapeutic products across multiple therapeutic areas and indications.

According to Vision Research Reports, the global viral vector and plasmid DNA manufacturing market size was estimated at around USD 5.37 billion

Pacific Neuroscience Institute® is thrilled to announce that Dale Bredesen, MD, has joined Pacific Neuroscience Institute®.

IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that William Ho, CEO and Co-founder, will present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference on Thursday, April 18th at 12:30pm ET.

Acumen Pharmaceuticals, Inc. will present the comprehensive clinical and biomarker results from its positive Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) in early AD during an Emerging Science Session at the American Academy of Neurology (AAN) 2024 Annual Meeting in Denver on April 16, 2024.

March of Dimes has awarded two doctors the Basil O’Connor Starter Scholar Research Awards, the organization’s signature grants for up-and-coming scientists embarking on lifelong research paths.

Nascent Biotech, Inc. announces that it is embarking on a fresh manufacturing run to ensure Pritumumab supplies are at maximum potency when patient dosing begins in the upcoming Phase II clinical trial.

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced two oral presentations highlighting XEN1101 clinical data at the American Academy of Neurology (AAN) 2024 Annual Meeting in Denver, CO.

Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd. (Zydus Group), today announced The Medicines and Healthcare products Regulatory Agency (MHRA) authorization of NULIBRY.